

### **The CytoTools AG is carrying out the phase II trial as planned; investment in DermaTools further increased**

- Intermediate results of the phase II trial for DermaPro® are now available and confirm the positive course so that the dosage determination can be concluded as planned
- DermaTools undertakes capital increase with a cash inflow of about 1.7 million EUR in fresh capital
- The CytoTools AG increases its share to over 62 %

Darmstadt, 8<sup>th</sup> March 2019 – The CytoTools AG (WKN: A0KFRJ; ISIN: DE000A0KFRJ1) is pleased to report on the expected successful course of the current dosage determination trial of DermaPro® in phase II. Accordingly, recruitment and treatment of the first 100 patients has been completed successfully. As planned, an intermediate evaluation was carried out and these interim findings confirm that the dosage determination trial can continue and be terminated as scheduled. During the intermediate evaluation, the trial continued so that now already 140 from a total of 200 patients have been included.

From today's perspective, all the required patients should be recruited before the end of April, and from this time onward, the treatment can be concluded within a maximum of 12 weeks.

At the same time, the decisive phase III trial is being prepared. Its ultimate design will be decided depending on the final results of the dosage determination trial. If it is confirmed here that the phase III trial in Europe (diabetic foot syndrome), beginning from the third quarter 2019, can be carried out with such a comparatively low expenditure, the management board will intensify the search for a partner already in 2020.

### **Further increase in the share of subsidiary DermaTools Biotech GmbH**

Within the scope of a cash capital increase for the sum of about 1.7 million EUR, the CytoTools AG increased its share in DermaTools Biotech GmbH from almost 60 % to 62 %, thus simultaneously providing the financial means for achieving the next clinical targets. DermaTools can therefore continue to concentrate fully on the development of DermaPro®



*This press release contains specific future oriented statements. These reflect the opinion of CytoTools on the date of this release. The actual results achieved by CytoTools could substantially deviate from the future-oriented statements made. CytoTools is not obligated to update these future-oriented statements.*

### **About CytoTools**

CytoTools AG is a German biotechnology company focused on translating the results of fundamental biology research on the mechanisms of cell growth and programmed cell death into novel therapies, that are designed to treat the cause of the disease rather than the symptoms. The company has developed a robust and diverse pipeline of self-developed chemical compounds and biopharmaceuticals with the potential to provide new treatment options in dermatology, cardiology and angiology, urology and oncology. CytoTools AG is structured as an investment and holding company and as such holds investments in its subsidiaries DermaTools Biotech GmbH (62 %) and CytoPharma GmbH (50%).

### **Contact:**

CytoTools AG

Dr. Mark Andre Freyberg

Klappacher Str. 126

D-64285 Darmstadt

Tel.: +49-6151-95158-12

Fax: +49-6151-95158-13

E-Mail: [freyberg@cytotools.de](mailto:freyberg@cytotools.de)

UBJ. GmbH

Ingo Janssen

Haus der Wirtschaft

Kapstadtring 10

D-22297 Hamburg

Tel.: +49-40-6378-5410

Fax: +49-40 6378-5423

E-Mail: [ir@ubj.de](mailto:ir@ubj.de)